Identification of CYP2C19*4B: pharmacogenetic implications for drug metabolism including clopidogrel responsiveness

doi:10.1038/tpj.2011.5

Pharmacogenomics J. Author manuscript; available in PMC 2012 August 1.

Published in final edited form as:

Pharmacogenomics J. 2012 August; 12(4): 297–305.

Published online 2011 March 1. doi: 10.1038/tpj.2011.5

PMCID: PMC3310336

NIHMSID: NIHMS340428

Identification of CYP2C19*4B: pharmacogenetic implications for drug metabolism including clopidogrel responsiveness

SA Scott, S Martis, I Peter, Y Kasai, R Kornreich, and RJ Desnick

Department of Genetics and Genomic Sciences, Mount Sinai School of Medicine, New York, NY, USA

Correspondence: Dr SA Scott, Department of Genetics and Genomic Sciences, Box 1497, Mount Sinai School of Medicine of New York University, One Gustave L Levy Place, New York, NY 10029, USA. Email: stuart.scott/at/mssm.edu

The publisher's final edited version of this article is available at Pharmacogenomics J

See other articles in PMC that cite the published article.

Abstract

CYP2C19 is a principal enzyme involved in the bioactivation of the antiplatelet prodrug clopidogrel and common CYP2C19 loss-of-function alleles are associated with adverse cardiovascular events. To assess the impact of the CYP2C19*17 increased activity allele in the Ashkenazi Jewish (AJ) and Sephardi Jewish (SJ) populations and to determine the frequencies of additional variant alleles, 250 AJ and 135 SJ individuals were genotyped for CYP2C19*2–*10, *12–*17, *22 and P-glycoprotein (ABCB1) c.3435C>T. Importantly, CYP2C19*4, a loss-of-function allele, was identified in linkage disequilibrium with *17. This novel haplotype, designated CYP2C19*4B, significantly alters the interpretation of CYP2C19 genotyping when testing *17. Moreover, genotyping CYP2C19*17 changed the frequency of extensive metabolizers from ~70 to ~40%, reclassifying ~30% as ultrarapid metabolizers. Combining CYP2C19 and ABCB1 identified ~1 in 3 AJ and ~1 in 2 SJ individuals at increased risk for adverse responses to clopidogrel. These data underscore the importance of including *4B and *17 when clinically genotyping CYP2C19.

Keywords: CYP2C19, CYP2C19*4B, CYP2C19*17, clopidogrel, Ashkenazi Jewish, Sephardi Jewish

Introduction

The human cytochrome P450 2C (CYP2C) subfamily of enzymes is comprised of CYP2C8, CYP2C9, CYP2C18 and CYP2C19, which together are involved in the hepatic metabolism of ~25% of prescription and over-the-counter drugs.¹ Like many other CYP450 superfamily members, the CYP2C19 gene is highly polymorphic with over 25 known variant alleles.^2,3 For example, CYP2C19*2 (c.681G>A; rs4244285) and *3 (p.W212X; rs4986893) are the most commonly studied CYP2C19 loss-of-function alleles and their frequencies vary among racial groups (average multiethnic allele frequencies of ~18 and ~2%, respectively).^4–6 In contrast to these and other variant CYP2C19 alleles with decreased enzyme activity (*4–*8), the *17 promoter variant allele (c.−806C>T; rs12248560) is unique in that it results in increased activity as a consequence of enhanced transcription.^7,8 Based on identified CYP2C19 genotypes, individuals can be categorized into four CYP2C19 metabolizer phenotypes:^9–11 ultrarapid (*1/*17 or *17/*17), extensive (*1/*1), intermediate (deficient allele heterozygote) and poor (deficient allele compound heterozygote or homozygote).

CYP2C19 is involved in the metabolism of various clinically important drugs, including some antiulcer medications, antidepressants, β-adrenoceptor blockers and the anticonvulsant drug S-mephenytoin.^4,12 However, recent attention has focused on its role in the bioactivation of the antiplatelet agent clopidogrel,^13,14 which is commonly prescribed in patients with acute coronary syndrome and those undergoing percutaneous coronary intervention. Importantly, carriers of CYP2C19 loss-of-function alleles have reduced responsiveness to clopidogrel with significantly increased risks of stent thrombosis, stroke, myocardial infarction and death following treatment.^11,15–19 However, these adverse effects may be reduced among patients with certain indications such as non-ST-segment elevation acute coronary syndrome and atrial fibrillation.²⁰ The growing body of literature implicating CYP2C19 loss-offunction alleles in adverse clopidogrel responses prompted the United States Food and Drug Administration to implement a recent boxed warning on the clopidogrel label describing the relationship between CYP2C19 pharmacogenetics and drug response, particularly noting the diminished effectiveness in poor metabolizers.²¹ Additionally, these studies offer a compelling rationale for pharmacogenetic-guided anti-platelet drug selection and/or dosing in this patient population.^22–26

In contrast to the deficient activity of CYP2C19 alleles, CYP2C19*17 recently has been associated with an enhanced platelet response to clopidogrel with an accompanying slight increase in bleeding risk during treatment.^27–30 CYP2C19*17 appears to be common in Caucasians and less so in Asian populations (allele frequencies of~20 and~5%, respectively);³¹ however, its frequency has not been adequately established in other racial and ethnic groups. Moreover, recent studies have suggested that previously reported CYP2C19 allele, genotype and metabolizer phenotype frequencies should be reassessed in light of the recent identification of the *17 allele.³²

We previously reported the CYP2C19*2–*8 allele frequencies for the Ashkenazi Jewish (AJ) population and found that they were similar to those in other European Caucasian populations.³³ Notably, the *4 (c.1A>G; rs28399504) null mutation frequency was found to be ~2%, slightly higher than its reported frequencies in Caucasian and Hong Kong Chinese cohorts (~0.6%).^34,35 To assess the impact of including *17 in AJ testing panels and to determine the population structure of additional variant CYP2C19 alleles in both the AJ and Sephardi Jewish (SJ) populations, we regenotyped the AJ individuals previously tested for CYP2C19*2–*8, for CYP2C19*2–*10, *12–*17 and *22, and compared these results with a large SJ cohort. Additionally, the ATP-binding cassette, subfamily B (MDR/TAP), member 1 (ABCB1) c.3435C>T (rs1045642) polymorphism recently associated with impaired clopidogrel absorption and adverse clinical response^17,36–38 was interrogated in both populations. By employing an expanded CYP2C19 genotyping panel coupled with allele-specific cloning and sequencing, our study identified a novel haplotype, designated CYP2C19*4B, that has important pharmacogenetic implications for drug metabolism, particularly when clinically assessing CYP2C19 for clopidogrel responsiveness among patients initiating antiplatelet therapy. Moreover, genotyping CYP2C19*17 in the AJ and SJ populations significantly changed the frequency of extensive metabolizers by reclassifying ~30% as ultrarapid metabolizers. Importantly, when combining all of the studied CYP2C19 and ABCB1 variants, ~1 in 3 AJ and ~1 in 2 SJ individuals may be at increased risk for adverse cardiovascular responses to clopidogrel.

Materials and methods

Specimens

Peripheral blood samples were obtained with informed consent from self-reported unrelated AJ (n=250) and SJ (n=135) individuals from the greater New York metropolitan area undergoing routine carrier screening for Jewish genetic diseases.^33,39,40 All personal identifiers were removed, and the samples were tested anonymously. Genomic DNA was isolated using the Puregene DNA Purification kit (Qiagen, Valencia, CA, USA) as per the manufacturer’s instructions.

Genotyping

The designations of all CYP2C19 alleles refer to those defined by the Cytochrome P450 Allele Nomenclature Committee (http://www.cypalleles.ki.se/cyp2c19.htm).³ Eleven variant CYP2C19 alleles (*2–*10, *13 and *17) were genotyped using the eSensor 2C19 Test (GenMark Diagnostics, Carlsbad, CA, USA) as per the manufacturer’s instructions. The wild-type CYP2C19*1 allele was assigned in the absence of other detectable variant alleles. Representative positive control samples for identified alleles were confirmed by bidirectional sequencing (see below).

Genotyping of CYP2C19*12, *14, *15, *16, *22 and ABCB1 c.3435C>T was performed using a multiplexed SNaPshot single base extension assay (Applied Biosystems, Carlsbad, CA, USA), whereby CYP2C19 exons 1, 4 and 9 were initially PCR amplified with exon 27 of ABCB1. Reactions were performed in 10 μl containing ~50 ng of DNA, 1× PCR buffer (Invitrogen, Carlsbad, CA, USA), 3.0mM MgCl₂, 0.2mM of each dNTP, forward and reverse primers (CYP2C19 exon 1: 0.4 μM; exon 4: 0.5 μM; exon 9: 0.2 μM; ABCB1 exon 27: 0.4 μM; Supplementary Table S1) and 1.0 unit of Platinum Taq DNA Polymerase (Invitrogen). Amplification consisted of an initial denaturation step at 94 °C for 5 min followed by 38 amplification cycles (94 °C for 30 s, 58 °C for 30 s and 72 °C for 1 min) and a final incubation at 72 °C for 5 min. Amplicons were digested with 3.0 units of shrimp alkaline phosphatase and 2.0 units of Exonuclease I (both from USB Corporation, Cleveland, OH, USA). SNaPshot primer extension reactions were performed in 10 μl containing 1× SNaPshot Reaction Mix (Applied Biosystems), 0.2 μM of each allele-specific primer (Supplementary Table S1) and 4.0 μl of PCR product. Following the recommended thermal cycling, samples were treated with 1.0 unit of shrimp alkaline phosphatase, electrophoresed on an ABI Prism 310 Genetic Analyzer, and analyzed using GeneMarker software v1.85 (SoftGenetics, State College, PA, USA). Representative positive control samples for identified alleles were confirmed by bidirectional sequencing (see below).

CYP2C19 promoter and exon 1 cloning

Cloning and allele-specific sequencing of a 1.2-kb fragment encompassing CYP2C19*17 (c.−806C>T) and *4 (c.1A>G) was performed on samples that harbored both alleles as determined by targeted genotyping. An initial PCR was performed in 25 μl containing ~100 ng of DNA, 1× Pfu DNA polymerase reaction buffer (Agilent Technologies, La Jolla, CA, USA), 0.2mM of each dNTP, 0.4 μM of forward and reverse primers (Supplementary Table S1) and 2.5 units of PfuTurbo Hotstart DNA polymerase (Agilent Technologies). Amplification consisted of an initial denaturation step at 95 °C for 5 min followed by 35 amplification cycles (95 °C for 30 s, 58 °C for 30 s and 72 °C for 2 min) and a final incubation at 72 °C for 10 min. A 3′-deoxyadenosine over-hang was added to blunt-ended amplicons by incubation with 1.0 unit of Platinum Taq DNA Polymerase (Invitrogen) at 72 °C for 10 min. These products were purified and cloned into the pCR2.1-TOPO vector using the TOPO TA Cloning Kit (Invitrogen) as per the manufacturer’s instructions. For each sample, 6 to 10 colonies were propagated and bidirectionally sequenced using M13 and T7 vector-specific primers. All plasmid sequence data were analyzed using Mutation Surveyor software v3.30 (SoftGenetics).

CYP2C19 sequencing

CYP2C19 exon sequencing was performed by an initial PCR in 25 μl containing ~100 ng of DNA, 1× PCR buffer (Invitrogen), 1.5mM MgCl₂, 0.2mM of each dNTP, 0.4 μM of forward and reverse primers and 1.0 unit of Platinum Taq DNA Polymerase (Invitrogen). Amplification consisted of an initial denaturation step at 95 °C for 5 min followed by 35 amplification cycles (95 °C for 30 s, T_a (Supplementary Table S1) for 30 s and 72 °C for 1 min) and a final incubation at 72 °C for 10 min. Amplicons were digested with 2.5 units of shrimp alkaline phosphatase and 10.0 units of Exonuclease I (both from USB Corporation), and bidirectionally sequenced using amplification primers and/or nested sequencing primers as noted in Supplementary Table S1. In addition, an upstream CYP2C19 promoter fragment encompassing the c.−3402C>T (rs11188072) allele common to *17 was sequenced in selected samples as described above. All bidirectional sequence data were analyzed using Mutation Surveyor software v3.30 (SoftGenetics).

Results

Identification of CYP2C19*4B

To assess the impact of including *17 in AJ testing panels and to determine the population structure of variant CYP2C19 alleles in the AJ population, 250 AJ individuals previously tested for CYP2C19*2–*8 were re-genotyped for CYP2C19*2–*10, *12, *13, *16, *17 and *22. The initial CYP2C19*1, *2, *4 and *17 allele frequencies detected among the 250 AJ individuals were 0.619, 0.145, 0.020 and 0.216, respectively; CYP2C19*3, *5–*10, *12, *13, *16 and *22 were not detected among the 500 AJ alleles tested. Of note, complete concordance for *2 and *4 was observed between the previously reported genotyping platform³³ and that used in the current study. However, interestingly, four subjects were identified with three alleles each: two with *2/ *4/*17 and two with *4/*17/*17, inappropriately resulting in 504 total alleles among the 250 individuals. Moreover, the genotype frequencies deviated from Hardy–Weinberg equilibrium as no AJ individuals were identified with a *1/*4 genotype, even though the *1 and *4 allele frequencies predicted that 2.5% of the population (approximately six individuals in 250) should have the genotype. In fact, all other *4 heterozygotes (n=6) were also heterozygous for *17, resulting in a *4/*17 genotype frequency (2.4%) greater than what was predicted (0.9%). Taken together, these results suggested that CYP2C19*4, a loss-of-function poor metabolizer allele,³⁴ occurred on a *17 background in the AJ population.

To confirm that CYP2C19*4 and *17 were in cis among the *4 carriers in our AJ cohort, a 1.2-kb promoter/exon 1 amplicon encompassing the *4 and *17 variants was PCR amplified from each informative carrier and cloned into the pCR2.1-TOPO vector. Six to 10 colonies from the eight *4 and *17 heterozygotes were propagated and bidirectionally sequenced, and in all individuals, the *4 and *17 variants were on the same CYP2C19 allele. To further define the coding sequence of this novel allele, all nine CYP2C19 exons and exon/intron boundaries were bidirectionally sequenced, which identified two additional coding variants (c.99C>T (rs17885098) and c.991A>G (rs3758581)) consistent with the previously defined *4 haplotype.^3,4,34

Detailed sequencing results of all identified single-nucleotide polymorphisms, including intronic variants, among the *4 carriers are summarized in Table 1. The identified haplotype of the novel allele (NG_008384.1:c.[−3402T; −806T; 1G; 99T; 991G]) was submitted for review by the Cytochrome P450 Allele Nomenclature Committee^2,3 and subsequently named CYP2C19*4B. All sequencing and genotyping data were correlated with known CYP2C19 haplotypes³ and the identified diplotypes among the *4B carriers, including their coding region variants, are illustrated in Figure 1.

Table 1

CYP2C19 sequencing results for the Ashkenazi Jewish (AJ) and Sephardi Jewish (SJ) CYP2C19*4 carriers

Figure 1

Sequence and genotyping results for the Ashkenazi Jewish (AJ) and Sephardi Jewish (SJ) CYP2C19*4B carriers. (a) Illustration of the CYP2C19 gene and location of relevant polymorphisms (not to scale). Exons are represented by numbered black boxes. (b) (more ...)

Interestingly, one *1/*4B AJ individual was found by sequencing to be heterozygous for the CYP2C19*15 (p.I19L; rs17882687) allele, suggesting a *4B/*15 genotype (Subject: AJ 8; Table 1; Figure 1). The unanticipated identification of *15 prompted its subsequent inclusion into the multiplexed SNaPshot assay, in addition to the neighboring CYP2C19*14 (p.L17P; rs55752064) allele (see Materials and methods).

CYP2C19 allele and genotype frequencies

After accounting for the novel CYP2C19*4B allele and incorporating *14 and *15 into the genotyping panel, the revised AJ CYP2C19 allele and genotype frequencies were in Hardy–Weinberg equilibrium and are summarized in Tables 2 and and3.3. The CYP2C19*1, *2, *4B, *15 and *17 allele frequencies among the 250 AJ individuals were 0.632, 0.146, 0.020, 0.004 and 0.198, respectively. Based on their genotypes, the reassigned metabolizer phenotypes in the AJ population were distributed as ultrarapid (29%), extensive (42%), intermediate (18%) and poor (4%) metabolizers.

Table 2

Ashkenazi Jewish (AJ) and Sephardi Jewish (SJ) CYP2C19 allele frequencies

Table 3

Ashkenazi Jewish (AJ) and Sephardi Jewish (SJ) CYP2C19 genotype frequencies

In addition to the AJ cohort, 135 individuals of SJ descent were genotyped for all 16 variant CYP2C19 alleles. Interestingly, in contrast to the AJ population, both the original CYP2C19*4A allele (without c.−806C>T) and the novel *4B allele (with c.−806C>T), as well as the *8 (p.W120R; rs41291556) loss-of-function allele, were detected in the SJ population. Like the AJ CYP2C19*4B carriers, all informative SJ carriers were confirmed by allele-specific cloning and sequencing (Table 1; Figure 1). The CYP2C19*1, *2, *4A, *4B, *8, *15 and *17 allele frequencies among the SJ individuals were 0.722, 0.096, 0.004, 0.011, 0.004, 0.004 and 0.159, respectively (Table 2). Although additional variant alleles were detected in the SJ compared with the AJ, the CYP2C19 allele and genotype frequencies did not reach statistical significance between the two populations (P=0.07 and 0.16, respectively). Based on their genotypes, the assigned metabolizer phenotypes in the SJ population were distributed as ultrarapid (27%), extensive (53%), intermediate (16%) and poor (3%) metabolizers (Table 3).

ABCB1 allele and genotype frequencies

Several studies have found that homozygous carriers of the ABCB1 c.3435C>T (p.I1145I) synonymous variant have higher rates of adverse cardiovascular events than c.3435C homozygotes during clopidogrel therapy, which was independent from and compounded by CYP2C19 loss-of-function alleles.^17,36–38 However, conflicting data have been reported regarding which allele (c.3435C or c.3435T) is associated with the increased risk.⁴¹ Supplementary Tables S2 and S3 summarize the identified ABCB1 c.3435C>T allele and genotype frequencies, which were statistically different between the AJ and SJ populations (P=0.0002 and 0.0005, respectively). Of note, ~1 in 13 (8.4%) AJ and ~1 in 5 (19.3%) SJ individuals were c.3435T homozygotes.

Combined CYP2C19 and ABCB1 frequencies

Figure 2 and Supplementary Table S4 summarize the combined CYP2C19 metabolizer phenotype and ABCB1 genotype frequency profiles for the AJ and SJ, which were statistically different between the two populations (P<0.0001). Of note, when combining the CYP2C19 and ABCB1 frequency data, ~60–65% of AJ and SJ individuals carried a CYP2C19 allele (*2, *4A, *4B, *8, *17) and/or ABCB1 genotype (c.3435T/T) that could influence their response to clopidogrel. However, increased risk for clopidogrel non-responsiveness and adverse cardiovascular events has largely been reported among individuals carrying a CYP2C19 loss-of-function allele and/or those with an ABCB1 c.3435T/T genotype.^17,38 Categorizing the AJ and SJ subjects using these specific criteria indicated that 34% of AJ (~1 in 3) and 43% of SJ (~1 in 2) individuals carried CYP2C19 and ABCB1 genotypes that conferred an increased risk for clopidogrel nonresponsiveness and/or adverse effects (P<0.0001; Figure 3; Supplementary Table S5).

Figure 2

Combined CYP2C19 and ABCB1 genotype frequency profiles in the Ashkenazi Jewish (AJ) and Sephardi Jewish (SJ) populations. Frequencies were subdivided based on CYP2C19 predicted metabolizer phenotype and ABCB1 c.3435C>T genotype. Genotypes with (more ...)

Figure 3

Combined genotype frequencies subdivided by CYP2C19 loss-of-function allele carrier status (noncarriers vs carriers) and ABCB1 c.3435C>T genotype (C/C+C/T vs T/T) in the Ashkenazi Jewish (AJ) and Sephardi Jewish (SJ) populations. Genotype categories (more ...)

Discussion

The growing body of literature on clopidogrel pharmacogenetics and the paucity of frequency data for variant CYP2C19 alleles beyond the commonly studied *2 and *3 loss-of-function alleles prompted our population structure investigation of CYP2C19 and ABCB1 in the AJ and SJ populations. Importantly, our study identified a novel CYP2C19 allele, designated CYP2C19*4B, in both Jewish ethnicities that has significant pharmacogenetic implications for drug metabolism, particularly when clinically assessing CYP2C19 for clopidogrel responsiveness. The haplotype of the CYP2C19*4B allele (NG_008384.1: c.[−3402T; −806T; 1G; 99T; 991G]) is a combination of two previously identified alleles, *4 (NG_008384.1:c.[1G; 99T; 991G]) and *17 (NG_008384.1:c.[−3402T; −806T; 99T; 991G]), each with opposing phenotypic consequences. CYP2C19*4 is a loss-of-function ‘poor metabolizer’ allele and *17 is an increased activity ‘ultrarapid metabolizer’ allele.^7,8,34

The c.1A>G mutation of CYP2C19*4 abolishes the ATG initiation codon and was originally identified by sequencing CYP2C19 in Caucasians who were poor mephenytoin metabolizers.³⁴ The defective activity of CYP2C19*4 was confirmed in vitro by its lack of recombinant protein expression in yeast and failure to translate CYP2C19 peptides in a coupled transcription/translation assay. However, CYP2C19*4 was able to transcribe mRNA in vitro, indicating that the failure of CYP2C19 protein expression was at the level of translation.³⁴ Consequently, CYP2C19*4B would also fail to produce CYP2C19 protein, regardless of the increased transcriptional capacity mediated by the upstream c.–806C>T promoter variant.

Although the frequency of CYP2C19*4B was only ~2% in the AJ and SJ populations, its inclusion in genotyping panels is important, particularly given the high frequency of CYP2C19*17 in Caucasian populations and the increasing interest in adding *17 to panels that include the commonly tested *2 and *3 alleles. For example, testing for *2, *3 and *17 without *4B would have misclassified ~1 in 25 AJ individuals, including eight intermediate metabolizers who would have been incorrectly classified as ultrarapid metabolizers and two poor metabolizers who would have been incorrectly classified as intermediate metabolizers. Testing for *2, *3 and *17 without *4B in the SJ would have misclassified ~1 in 45 individuals, including one intermediate metabolizer who would have been incorrectly classified as an ultrarapid metabolizer and two poor metabolizers who would have been incorrectly classified as intermediate metabolizers.

Recently, CYP2C19*17 has been reported to be in linkage disequilibrium with the neighboring CYP2C8*1 and CYP2C9*1 wild-type alleles among Nordic individuals.⁴² The identified linkage disequilibrium between *17 and *4 (comprising the *4B allele) in the AJ and SJ populations was not observed in the Nordic cohort nor was *4B identified in a recent CYP2C19 sequencing study of Han Chinese individuals,⁴³ together suggesting that *4B may be specific to Jewish subpopulations. However, preliminary studies in our laboratory have identified the *4B allele in both Caucasians and Hispanics.

The inclusion of CYP2C19*17 alone also significantly altered the frequencies of the predicted metabolizer phenotypes. For example, CYP2C19*17 changed the frequency of extensive metabolizers (*1/*1) in both populations from ~70 to ~40%, with ~30% of individuals reclassified as ultrarapid metabolizers (*1/*17 or *17/*17). Very recently, Sibbing et al.²⁹ assessed the impact of CYP2C19*2 and *17 on clopidogrel responsiveness among patients undergoing clopidogrel maintenance therapy. They determined that individuals with a *1/*17 or *17/*17 genotype had lower residual ADP-induced platelet aggregation compared with wild-type individuals, suggesting that the *17 allele resulted in the enhanced bioactivation of clopidogrel.²⁹ In addition, they reported that individuals with a *2/*17 genotype had higher residual platelet aggregation compared with wildtype individuals, but less than those carrying *2 without *17, suggesting that the ultrarapid *17 allele could not completely compensate for a heterozygous null allele. Although this implies that individuals with a *2/*17 genotype (or other loss-of-function allele/*17 compound heterozygotes) are intermediate metabolizers, in the absence of independent validation these genotypes were provisionally classified as having an ‘unknown’ metabolizer phenotype in our current study.

The CYP2C19*15 variant allele was originally identified in an African population;⁴⁴ however, its phenotypic consequence is unknown. Therefore, the detected *1/*15, *2/*15 and *4B/*15 individuals in our study were also classified as having an ‘unknown’ metabolizer phenotype (Table 3). Although missense alterations at the amino-terminal region of CYP450 enzymes are often considered benign,⁴⁴ aberrant splicing, protein misfolding and/or expression alterations mediated by the CYP2C19*15 allele could not be ruled out. As more ethnic subpopulation-specific CYP2C19 alleles are identified and commercial genotyping panels are expanded, appropriate clinical assessment of unique genotype combinations will be critical to assign the appropriate metabolizer phenotypes and for the clinical application of expanded CYP2C19 pharmacogenetic panels, particularly for clopidogrel responsiveness testing.

The ABCB1 gene encodes the P-glycoprotein membrane efflux transporter, which is involved in the intestinal absorption and bioavailability of clopidogrel. Previously, the c.3435C>T allele was associated with duodenal protein expression and lower bioavailability of established P-glycoprotein substrates,^45,46 suggesting that ABCB1 c.3435C>T might influence clopidogrel efflux and drug bioavailability. ³⁶ However, given the conflicting data available on c.3435C>T and P-glycoprotein expression,^45–47 expanded studies are warranted to identify ABCB1 haplotypes and assess their relationship to gene expression. Despite this discrepancy, some large clinical studies found that c.3435T/ T patients had a higher rate of adverse cardiovascular events than c.3435C homozygotes during clopidogrel therapy, which was independent from and compounded by CYP2C19 loss-of-function alleles.^17,38 Our study identified a high frequency of c.3435C>T homozygotes in both Jewish populations (~10–20%), and when combined with the CYP2C19 data, the majority (~60–65%) of AJ and SJ individuals harbored a CYP2C19 and/or ABCB1 genotype that could influence their response to clopidogrel.

In conclusion, our study identified a novel allele in the AJ and SJ populations, designated CYP2C19*4B, that is a variant of the *4 loss-of-function allele occurring on a *17 increased transcriptional background. The high frequency of *17 without the *4 variant in our cohorts suggests that the c.−806C>T (*17) promoter variant predates the initial occurrence of the c.1A>G (*4) allele. Three other important conclusions can be made from our population structure study: CYP2C19*4B would significantly alter the interpretation of CYP2C19 genotyping when testing for *17 without the *4 mutation; inclusion of CYP2C19*17 in our genotyping panel significantly changed the frequency of extensive metabolizers in the AJ and SJ cohorts; and, when combining CYP2C19 and ABCB1 genotypes, ~1 in 3 AJ and ~1 in 2 SJ individuals could have an increased risk for an adverse response to the commonly prescribed antiplatelet prodrug clopidogrel. Taken together, these data underscore the importance of including both *4B and *17, in addition to the commonly tested *2 and *3 alleles, when clinically assessing CYP2C19 for pharmacogenetic-guided dosing, particularly when testing for clopidogrel responsiveness among patients initiating antiplatelet therapy. Moreover, these data suggest that additional prospective clinical studies on clopidogrel response are warranted that include the common ABCB1 c.3435C>T polymorphism in addition to variant CYP2C19 alleles.

Supplementary Material

Supplemental Data

Click here to view.^{(66K, doc)}

Acknowledgments

We thank Dr Joseph M Sweeny, Mount Sinai Medical Center, New York, and Dr Sarah Sim, Karolinska Institutet, Stockholm, Sweden, for critical reading of the manuscript. This research was supported in part by a research training grant (5 T32 GM082773) and a grant (UL1RR029887) for the Mount Sinai Institutes for Clinical and Translational Sciences from the National Center for Research Resources, National Institutes of Health. eSensor 2C19 Test reagents for this study were supplied by GenMark Diagnostics (Carlsbad, CA, USA).

Footnotes

Conflict of interest

The authors declare no conflict of interest.

References

1. Ingelman-Sundberg M. Human drug metabolising cytochrome P450 enzymes: properties and polymorphisms. Naunyn Schmiedebergs Arch Pharmacol. 2004;369:89–104. [PubMed]

2. Ingelman-Sundberg M, Oscarson M, Daly AK, Garte S, Nebert DW. Human cytochrome P-450 (CYP) genes: a web page for the nomenclature of alleles. Cancer Epidemiol Biomarkers Prev. 2001;10:1307–1308. [PubMed]

3. Sim SC, Ingelman-Sundberg M. The human cytochrome P450 (CYP) allele nomenclature website: a peer-reviewed database of CYP variants and their associated effects. Hum Genomics. 2010;4:278–281. [PMC free article] [PubMed]

4. Goldstein JA. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol. 2001;52:349–355. [PubMed]

5. Xie HG, Kim RB, Wood AJ, Stein CM. Molecular basis of ethnic differences in drug disposition and response. Annu Rev Pharmacol Toxicol. 2001;41:815–850. [PubMed]

6. Goldstein JA, Ishizaki T, Chiba K, de Morais SM, Bell D, Krahn PM, et al. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics. 1997;7:59–64. [PubMed]

7. Sim SC, Risinger C, Dahl ML, Aklillu E, Christensen M, Bertilsson L, et al. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther. 2006;79:103–113. [PubMed]

8. Rudberg I, Mohebi B, Hermann M, Refsum H, Molden E. Impact of the ultrarapid CYP2C19*17 allele on serum concentration of escitalopram in psychiatric patients. Clin Pharmacol Ther. 2008;83:322–327. [PubMed]

9. Inomata S, Nagashima A, Itagaki F, Homma M, Nishimura M, Osaka Y, et al. CYP2C19 genotype affects diazepam pharmacokinetics and emergence from general anesthesia. Clin Pharmacol Ther. 2005;78:647–655. [PubMed]

10. Furuta T, Sugimoto M, Shirai N, Ishizaki T. CYP2C19 pharmacogenomics associated with therapy of Helicobacter pylori infection and gastro-esophageal reflux diseases with a proton pump inhibitor. Pharmacogenomics. 2007;8:1199–1210. [PubMed]

11. Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009;360:354–362. [PubMed]

12. Desta Z, Zhao X, Shin JG, Flockhart DA. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet. 2002;41:913–958. [PubMed]

13. Giusti B, Gori AM, Marcucci R, Saracini C, Sestini I, Paniccia R, et al. Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10+12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients. Pharmacogenet Genomics. 2007;17:1057–1064. [PubMed]

14. Hulot JS, Bura A, Villard E, Azizi M, Remones V, Goyenvalle C, et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood. 2006;108:2244–2247. [PubMed]

15. Collet JP, Hulot JS, Pena A, Villard E, Esteve JB, Silvain J, et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet. 2009;373:309–317. [PubMed]

16. Shuldiner AR, O’Connell JR, Bliden KP, Gandhi A, Ryan K, Horenstein RB, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA. 2009;302:849–857. [PubMed]

17. Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, Meneveau N, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009;360:363–375. [PubMed]

18. Hulot JS, Collet JP, Silvain J, Pena A, Bellemain-Appaix A, Barthelemy O, et al. Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis. J Am Coll Cardiol. 2010;56:134–143. [PubMed]

19. Sofi F, Giusti B, Marcucci R, Gori AM, Abbate R, Gensini GF. Cytochrome P450 2C19(*)2 polymorphism and cardiovascular recurrences in patients taking clopidogrel: a meta-analysis. Pharmacogenomics J. 2010 Epub ahead of print. [PubMed]

20. Paré G, Mehta SR, Yusuf S, Anand SS, Connolly SJ, Hirsh J, et al. Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N Engl J Med. 2010;363:1704–1714. [PubMed]

21. [Accessed 13 December 2010.];FDA Drug Safety Communication: reduced effectiveness of Plavix (clopidogrel) in patients who are poor metabolizers of the drug. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm203888.htm.

22. Ellis KJ, Stouffer GA, McLeod HL, Lee CR. Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations. Pharmacogenomics. 2009;10:1799–1817. [PubMed]

23. Holmes DR, Jr, Dehmer GJ, Kaul S, Leifer D, O’Gara PT, Stein CM. ACCF/ AHA Clopidogrel clinical alert: approaches to the FDA ‘boxed warning’: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association. Circulation. 2010;122:537–557. [PubMed]

24. Hulot JS, Wuerzner G, Bachelot-Loza C, Azizi M, Blanchard A, Peyrard S, et al. Effect of an increased clopidogrel maintenance dose or lansoprazole co-administration on the antiplatelet response to clopidogrel in CYP2C19-genotyped healthy subjects. J Thromb Haemost. 2010;8:610–613. [PubMed]

25. Roden DM, Shuldiner AR. Responding to the clopidogrel warning by the US food and drug administration: real life is complicated. Circulation. 2010;122:445–448. [PMC free article] [PubMed]

26. Seip RL, Duconge J, Ruano G. Implementing genotype-guided antithrombotic therapy. Future Cardiol. 2010;6:409–424. [PMC free article] [PubMed]

27. Frere C, Cuisset T, Gaborit B, Alessi MC, Hulot JS. The CYP2C19*17 allele is associated with better platelet response to clopidogrel in patients admitted for non-ST acute coronary syndrome. J Thromb Haemost. 2009;7:1409–1411. [PubMed]

28. Sibbing D, Koch W, Gebhard D, Schuster T, Braun S, Stegherr J, et al. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation. 2010;121:512–518. [PubMed]

29. Sibbing D, Gebhard D, Koch W, Braun S, Stegherr J, Morath T, et al. Isolated and interactive impact of common CYP2C19 genetic variants on the antiplatelet effect of chronic clopidogrel therapy. J Thromb Haemost. 2010;8:1685–1693. [PubMed]

30. Tiroch KA, Sibbing D, Koch W, Roosen-Runge T, Mehilli J, Schomig A, et al. Protective effect of the CYP2C19 *17 polymorphism with increased activation of clopidogrel on cardiovascular events. Am Heart J. 2010;160:506–512. [PubMed]

31. Li-Wan-Po A, Girard T, Farndon P, Cooley C, Lithgow J. Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17. Br J Clin Pharmacol. 2010;69:222–230. [PubMed]

32. Ragia G, Arvanitidis KI, Tavridou A, Manolopoulos VG. Need for reassessment of reported CYP2C19 allele frequencies in various populations in view of CYP2C19*17 discovery: the case of Greece. Pharmacogenomics. 2009;10:43–49. [PubMed]

33. Scott SA, Edelmann L, Kornreich R, Erazo M, Desnick RJ. CYP2C9, CYP2C19 and CYP2D6 allele frequencies in the Ashkenazi Jewish population. Pharmacogenomics. 2007;8:721–730. [PubMed]

34. Ferguson RJ, De Morais SM, Benhamou S, Bouchardy C, Blaisdell J, Ibeanu G, et al. A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin. J Pharmacol Exp Ther. 1998;284:356–361. [PubMed]

35. Garcia-Barcelo M, Chow LY, Kum Chiu HF, Wing YK, Shing Lee DT, Lam KL, et al. Frequencies of defective CYP2C19 alleles in a Hong Kong Chinese population: detection of the rare allele CYP2C19*4. Clin Chem. 1999;45:2273–2274. [PubMed]

36. Taubert D, von Beckerath N, Grimberg G, Lazar A, Jung N, Goeser T, et al. Impact of P-glycoprotein on clopidogrel absorption. Clin Pharmacol Ther. 2006;80:486–501. [PubMed]

37. Spiewak M, Malek LA, Kostrzewa G, Kisiel B, Serafin A, Filipiak KJ, et al. Influence of C3435T multidrug resistance gene-1 (MDR-1) polymorphism on platelet reactivity and prognosis in patients with acute coronary syndromes. Kardiol Pol. 2009;67:827–834. [PubMed]

38. Mega JL, Close SL, Wiviott SD, Shen L, Walker JR, Simon T, et al. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet. 2010;376:1312–1319. [PMC free article] [PubMed]

39. Scott SA, Edelmann L, Kornreich R, Desnick RJ. Warfarin pharmacogenetics: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations. Am J Hum Genet. 2008;82:495–500. [PubMed]

40. Scott SA, Edelmann L, Liu L, Luo M, Desnick RJ, Kornreich R. Experience with carrier screening and prenatal diagnosis for 16 Ashkenazi Jewish genetic diseases. Hum Mutat. 2010;31:1240–1250. [PMC free article] [PubMed]

41. Wallentin L, James S, Storey RF, Armstrong M, Barratt BJ, Horrow J, et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet. 2010;376:1320–1328. [PubMed]

42. Pedersen RS, Brasch-Andersen C, Sim SC, Bergmann TK, Halling J, Petersen MS, et al. Linkage disequilibrium between the CYP2C19*17 allele and wildtype CYP2C8 and CYP2C9 alleles: identification of CYP2C haplotypes in healthy Nordic populations. Eur J Clin Pharmacol. 2010;66:1199–1205. [PubMed]

43. Zhou Q, Yu XM, Lin HB, Wang L, Yun QZ, Hu SN, et al. Genetic polymorphism, linkage disequilibrium, haplotype structure and novel allele analysis of CYP2C19 and CYP2D6 in Han Chinese. Pharmacogenomics J. 2009;9:380–394. [PubMed]

44. Blaisdell J, Mohrenweiser H, Jackson J, Ferguson S, Coulter S, Chanas B, et al. Identification and functional characterization of new potentially defective alleles of human CYP2C19. Pharmacogenetics. 2002;12:703–711. [PubMed]

45. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA. 2000;97:3473–3478. [PubMed]

46. Nakamura T, Sakaeda T, Horinouchi M, Tamura T, Aoyama N, Shirakawa T, et al. Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects. Clin Pharmacol Ther. 2002;71:297–303. [PubMed]

47. Owen A, Goldring C, Morgan P, Chadwick D, Park BK, Pirmohamed M. Relationship between the C3435T and G2677T(A) polymorphisms in the ABCB1 gene and P-glycoprotein expression in human liver. Br J Clin Pharmacol. 2005;59:365–370. [PubMed]

48. Cascorbi I, Gerloff T, Johne A, Meisel C, Hoffmeyer S, Schwab M, et al. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther. 2001;69:169–174. [PubMed]